Neogenomics Inc Q3 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: David Michael Westenberg - Guggenheim Securities, LLC, Research Division - Analyst : David Westenberg at Guggenheim Securities. Yes. Apologies. I did want to ask a little bit more of a long-term question, but I am getting questions as well on the guidance here for Q4. Could you -- I'm actually thinking about a little bit more of the top line. Your commentary around Florida I think is definitely consistent with kind of the checks that we got. That has since subsided, and I think the subsiding of that was roughly 3 weeks ago. Can you help us maybe conceptualize a little bit more of your commentary around maybe slow start to clinical trial kind of delay? And it's similar kind of question to Andrew in terms of like where we stand today. Could we have seen makeup demand maybe in -- from delta delays in October -- I mean, in August/September starting to hit now, and maybe there's some upside to that guidance. Again, it seems very -- we totally understand the Q3 thing. It's just a little tougher to conceptualize the Q4. And again, I wish I could have asked a strategic question, but that's the inbounds I'm getting.